Rameda Pharmaceuticals
Karim Afifi is an experienced professional in the pharmaceutical industry, currently serving as a Product Manager at Rameda Pharmaceuticals since March 2023. Prior to this role, Karim held various positions at Novartis, including Supreme Product Specialist and Medical Representative from June 2015 to March 2023. Karim's earlier experience includes working as a Product Specialist at LEO Pharma and as a Medical Representative at Global Napi Pharmaceuticals. Additionally, Karim worked as a Community Pharmacist and Shift Manager at Seif Group from August 2011 to April 2013. Karim holds a Bachelor's degree in Pharmaceutical Sciences from Cairo University, obtained between 2006 and 2011, following completion of secondary education at Urman Secondary School.
Rameda Pharmaceuticals
Our Vision: To become the most valuable emerging pharmaceutical company in Egypt. Our Mission: To provide our customers quality health care solutions in a cost effective manner by developing products and services that satisfy their health requirements. Establishment Rameda began operations in 1994 and was established by a group of Gulf investors with the intention of creating one of the largest pharmaceutical operations in the region. Owners hired V-Konsult of Germany to create a state-of-the art design. Contracted British Carter Construction company to build the Rameda’s facilities. Partnership with Alcon In 1999, Rameda entered into an agreement with Alcon to manufacture – under license - their ophthalmology products. In order to guarantee the quality of their products, Alcon built one of the highest quality eye production facilities in the region at Rameda. Quality enhancement Rameda renewed the syrup production to become GMP (Good Manufacturing Practice). A new Beginning In 2011, Compass Capital led a consortium of private equity investors for the acquisition of 100% of Rameda. Compass Capital plans to establish Rameda as a regional leader in the industry. To execute this strategy Rameda hired a new management team with a proven track record to complement the existing team. Company has commissioned M+W Group to transform solid dosage and beta lactam areas into GMP. Brining entire facility to compliance.